DC Bead Brochure Archive

DC Bead (Hepatocellular Carcinoma)

April 2009

Liver Piece; protect healthy liver

Greater Tolerability, Increased efficacy, More Safely... for more patients;

Protecting your Patients (Minimise the toxicity of TACE, for your patients and you)

October 2008

PRECISION V Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation.  Initial Data Release

PRECISION V prospective randomisierte Studie von Doxorubicin für die Behandlung des hepatozellulären Karzinoms durch Embolisation mit Medikamente-freisetzenden Beads

PRECISION V Etude clinique prospective randomisée contrôlée du traitement du carcinome hépatocellulaire par chimioembolisation avec des microsphères d'embolisation chargeables

PRECISION V Studio randomizzato prospettico sull'utilizzo della Doxorubicina Mediante chemioembolizzazione con microsfere a rilascio di farmaco nella terapia dell' Epatocarcinoma

Estudio Prospectivo Randomizado en el Tratamiento del Carcinoma Hepatocelular mediante Embolización con Esferas Cargadas de Doxorrubicina

September 2008

Histo-pathological Response to Doxorubicin PRECISION TACE with DC Bead in Hepatocellular Carcinoma (Summary of ILCA 2008 Abstracts)

eRFA pamphlet:  Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma:  A pilot clinical study;

November 2007

PRECISION TACE with DC Bead™: Addressing the challenge of improved survival in hepatocellular carcinoma; November 2007

TACE SUPERSELETTIVA con DC Bead™: Raccoglie la sfida di una maggiore sopravvivenza nel carcinoma epatocellulare

PRECISION TACE avec DC Bead™: Amelioration du taux de survie dans les cas de carcinome hépatocellulaire

PRECISION TACE con DC Bead™: Respondiendo al reto que supone aumentar la supervivencia en el carcinoma hepatoculular

May 2006

Drug Delivery Embolisation System for PRECISION TACE: Less More Every time

DC Bead (DEBIRI for Metastatic Colorectal Cancer)

April 2009

DC Bead with irinotecan, offering the benefits of DC Bead to more patients

DC Bead with irinotecan, CE approved for loading with irinotecan, offering the benefits of DC Bead to more patients

DC Bead (HCC and MCC)

September 2008

Scientific Presentations and Abstracts Scheduled for CIRSE 2008 (including updated DC Bead Bibliography slides and DC Bead Technical Information booklet)

DC Bead for the pathological downstage of primary and metastatic liver cancer

Regulatory notices and product safety data

Worldwide (excluding USA and Canada)

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead instructions for use.

USA

DC Bead is not currently available for sale or distribution in the USA. DC Bead has not been submitted for approval to the FDA.

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.